Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07725523) titled 'Safety and Efficacy of OTL78 (Zopocianine)' on July 21.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Clinton Bahler
Condition:
Prostate Cancer Surgery
Prostate Cancer Metastatic Disease
Intervention:
Drug: 0.06mg/kg ZOPOCIANINE given 1-7 days prior to surgery...
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First Enrollment: September 2026
Target Sample Size: 36
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/...